On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly

Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded glucagon-like peptide-1 receptor agonists (GLP-1RAs), ending a long-running feud that had spiralled into legal proceedings.

Shares in Hims & Hers Health saw their largest same-day jump on record Monday after the beleaguered telehealth company struck an agreement with Novo Nordisk. Still, analysts aren’t rushing to recommend the stock. Hims announced Monday that it had hashed ...

Wall Street's major averages ended lower on Friday after nonfarm payrolls unexpectedly contracted in February and oil prices continued to rise. The benchmark S&P 500 closed -1.3%, while the Nasdaq Composite finished -1.

Wondering whether Hims & Hers Health is starting to look attractively priced, or if the market is still getting ahead of itself? This article walks through what the numbers are really saying about its value.